Skip to main content

Olga Simó Servat

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Olga Simó Servat

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Clinical development of RetSit@, a first-in-class neuroprotective drug to treat Early Stages of Diabetic Retinopathy

IP: Rafael Simó Canonge
Collaborators: Olga Simó Servat, Marta Garrido Marin, Miguel Angel Zapata Victori
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 602031
Reference: CPP2023-010602
Duration: 01/10/2024 - 30/09/2027

Ministerio de Ciencia

Individualización de la Monitorización continua de glucosa en la población anciana con diabetes mellitus tipo 2 en función del Estado cognitivo

IP: Monica Sanchez Bartres
Collaborators: Angel Michael Ortiz Zúñiga, Ana Maria Ortiz de Urbina Olive, Judit Amigó Farran, Mercè Abad Martín, Olga Simó Servat, Pedro Alejandro Gil Millán
Funding agency: Sociedad Española de Diabetes
Funding: 20000
Reference: SED/SANCHEZ/2023
Duration: 01/12/2023 - 31/05/2025

Resistencia a la insulina en la diabetes tipo 2: clarificando el mecanismo patogénico de la resistencia a la insulina miocárdica y los efectos de tratamientos con GLP-1 RA y SGLT2i

IP: José Raul Herance Camacho
Collaborators: Sofia Rodriguez Fernandez, Sergi Velasco Vila, Clara Ramírez Serra, Azahara Maria Palomar Muñoz, Cristina Gamez Cenzano, Jana Vidal Otero, Carolina Aparicio Gomez, Alberto Roque Pérez, Resistencia a la insulina en la diabetes tipo 2: clarificando el mecanismo patogénico de la resistencia a la insulina miocárdica, Resistencia a la insulina en la diabetes tipo 2: clarificando el mecanismo patogénico de la resistencia a la insulina miocárdica, Mercè Abad Martín, Olga Simó Servat, Pedro Alejandro Gil Millán, Maria Nazarena Pizzi, Emily Betancourt Fernández, Enrique Franky Vargas, Resistencia a la insulina en la diabetes tipo 2: clarificando el mecanismo patogénico de la resistencia a la insulina miocárdica, Martha Sahylí Ortega Pijeira
Funding agency: Instituto de Salud Carlos III
Funding: 252500
Reference: PI24/01356
Duration: 01/01/2025 - 31/12/2027

Utilitat de la inteligència artificial en l’anàlisi d’imatges de retina per identificar els pacients amb major risc de progressió de la retinopatia diabètica en el món real

IP: Olga Simó Servat
Collaborators: -
Funding agency: Associació Catalana de Diabetis
Funding: 10000
Reference: ACD/PROJECTES22/SIMO
Duration: 09/03/2023 - 08/03/2025

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Cristina Aguilera Martin

Cristina Aguilera Martin

Main researcher
Clinical Pharmacology
Read more
Yolanda Cámara Navarro

Yolanda Cámara Navarro

Main researcher
Neuromuscular and Mitochondrial Pathology
Read more
Daniel Malet Hernández

Daniel Malet Hernández

New Technologies and Craniofacial Microsurgery
Read more
José Alegre Martin

José Alegre Martin

Rheumatology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.